Skip to main navigation Skip to search Skip to main content

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial

  • Anne Laure Sellier-Leclerc
  • , Daniella Magen
  • , Hadas Shasha-Lavsky
  • , Eva Simkova
  • , Arnaud Devresse
  • , Fitsum Guebre-Egziabher
  • , Mini Michael
  • , John C. Lieske
  • , Yaacov Frishberg
  • , Sevcan A. Bakkaloglu
  • , Chebl Mourani
  • , Rola Saqan
  • , Richard Singer
  • , Isabella Guzzo
  • , Nune Makarova
  • , Richard Willey
  • , Cristin Kaspar
  • , John M. Gansner
  • , Jaap W. Groothoff
  • Hospices civils de Lyon
  • Rambam Health Care Campus Israel
  • Western Galilee Medical Center of Nahariya
  • Al Jalila Children's Hospital
  • Université catholique de Louvain
  • Hôpital Édouard Herriot
  • Texas Children's Hospital Houston
  • Mayo Clinic Rochester, MN
  • Shaare Zedek Medical Center
  • Hebrew University of Jerusalem
  • Gazi University
  • Hôtel Dieu de France University Hospital
  • Jordan University of Science and Technology
  • Canberra Health Services
  • IRCCS Ospedale pediatrico Bambino Gesù - Roma
  • Alnylam Pharmaceuticals
  • University of Amsterdam

Research output: Contribution to journalLetterpeer-review

8 Scopus citations
Original languageEnglish
Pages (from-to)285-288
Number of pages4
JournalAmerican Journal of Kidney Diseases
Volume86
Issue number2
Early online date13 Mar 2025
DOIs
StatePublished - Aug 2025
Externally publishedYes

Cite this